In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 478-480

  Saravolatz, Louis D ^a   Pawlak, Joan ^a   Johnson, Leonard B ^a   Husain, Nasir ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; METICILLIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DAPTOMYCIN NON SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; IN VITRO STUDY; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CEPHALOSPORINS; DAPTOMYCIN; DNA FINGERPRINTING; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 77957658300     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.07.016     Document Type: Letter

References (6)

1. Hebeisen P., Heinze-Krauss I., Angehrn P., Hohl P., Page M.G., Then R.L. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001, 45:825-836.
2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. Document M100-S18. Wayne, PA: CLSI; 2008.
3. Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA: CLSI; 1999.
4. Saravolatz L.D., Pawlak J., Johnson L.B. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents 2010, 36:69-72.
5. Bogdanovich T., Ednie L.M., Shapiro S., Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005, 49:4210-4219.
6. Zhanel G.G., Voth D., Nichol K., Karlowsky J.A., Noreddin A.M., Hoban D.J. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 2009, 64:364-369.